title: Activation of endogenous GABAA channels on airway smooth muscle potentiates isoproterenol-mediated relaxation.
abstract: Reactive airway disease predisposes patients to episodes of acute smooth muscle mediated bronchoconstriction. We have for the first time recently demonstrated the expression and function of endogenous ionotropic GABA(A) channels on airway smooth muscle cells. We questioned whether endogenous GABA(A) channels on airway smooth muscle could augment beta-agonist-mediated relaxation. Guinea pig tracheal rings or human bronchial airway smooth muscles were equilibrated in organ baths with continuous digital tension recordings. After pretreatment with or without the selective GABA(A) antagonist gabazine (100 muM), airway muscle was contracted with acetylcholine or beta-ala neurokinin A, followed by relaxation induced by cumulatively increasing concentrations of isoproterenol (1 nM to 1 muM) in the absence or presence of the selective GABA(A) agonist muscimol (10-100 muM). In separate experiments, guinea pig tracheal rings were pretreated with the large conductance K(Ca) channel blocker iberiotoxin (100 nM) after an EC(50) contraction with acetylcholine but before cumulatively increasing concentrations of isoproterenol (1 nM to 1 uM) in the absence or presence of muscimol (100 uM). GABA(A) activation potentiated the relaxant effects of isoproterenol after an acetylcholine or tachykinin-induced contraction in guinea pig tracheal rings or an acetylcholine-induced contraction in human endobronchial smooth muscle. This muscimol-induced potentiation of relaxation was abolished by gabazine pretreatment but persisted after blockade of the maxi K(Ca) channel. Selective activation of endogenous GABA(A) receptors significantly augments beta-agonist-mediated relaxation of guinea pig and human airway smooth muscle, which may have important therapeutic implications for patients in severe bronchospasm.
authors.affiliation: Dept. of Anesthesiology, College of Physicians and Surgeons of Columbia Univ., 650 W. 168 St., P&S Box 46, New York, NY, USA. gg2125@columbia.edu
authors.forename: George
authors.initials: G
authors.lastname: Gallos
authors.forename: Neil R
authors.initials: NR
authors.lastname: Gleason
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.forename: Sang-Woo
authors.initials: SW
authors.lastname: Pak
authors.forename: J R
authors.initials: JR
authors.lastname: Sonett
authors.forename: Jay
authors.initials: J
authors.lastname: Yang
authors.forename: Charles W
authors.initials: CW
authors.lastname: Emala
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D016084:Bronchoconstriction / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D018756:GABA Antagonists / Q000494:pharmacology; D006168:Guinea Pigs; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology*; D009126:Muscle Relaxation / Q000187:drug effects*; D009130:Muscle, Smooth / Q000378:metabolism*; D015288:Neurokinin A / Q000031:analogs & derivatives / Q000494:pharmacology; D009924:Organ Culture Techniques; D010446:Peptide Fragments / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D011724:Pyridazines / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000378:metabolism*; D014132:Trachea / Q000378:metabolism*; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D000318:Adrenergic beta-Agonists; D018756:GABA Antagonists; D010446:Peptide Fragments; D010455:Peptides; D011724:Pyridazines; D011963:Receptors, GABA-A; D014665:Vasodilator Agents; C064218:neurokinin A (4-10), beta-Ala(8)-; C064719:iberiotoxin; D015288:Neurokinin A; C049853:gabazine; D000251:Adenosine Triphosphatases; C029321:calcium potassium ATPase; D007545:Isoproterenol; D000109:Acetylcholine
references.citation: J Physiol. 1992;453:197-218
references.pmid: 1281502
references.citation: J Clin Invest. 1994 Jan;93(1):371-9
references.pmid: 7904270
references.citation: Am J Respir Crit Care Med. 2002 Aug 1;166(3):340-5
references.pmid: 12153967
references.citation: Nature. 1989 Sep 14;341(6238):152-4
references.pmid: 2550823
references.citation: Am J Physiol. 1995 Nov;269(5 Pt 1):L645-52
references.pmid: 7491984
references.citation: Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L923-31
references.pmid: 16829628
references.citation: Nat Med. 2007 Jul;13(7):862-7
references.pmid: 17589520
references.citation: J Clin Invest. 1996 Jun 1;97(11):2593-600
references.pmid: 8647953
references.citation: Eur J Pharmacol. 2006 Feb 15;531(1-3):9-12
references.pmid: 16412418
references.citation: Annu Rev Physiol. 1996;58:115-41
references.pmid: 8815788
references.citation: J Pharmacol Exp Ther. 1990 Nov;255(2):697-706
references.pmid: 1700817
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):437-41
references.pmid: 14530906
references.citation: Anesthesiology. 2005 Jan;102(1):117-24
references.pmid: 15618795
references.citation: J Neurosci. 1994 May;14(5 Pt 1):2503-14
references.pmid: 8182424
references.citation: J Appl Physiol (1985). 1993 Apr;74(4):1879-84
references.pmid: 8099905
references.citation: Am J Physiol. 1997 Aug;273(2 Pt 1):C509-19
references.pmid: 9277348
references.citation: Eur J Pharmacol. 1988 Apr 27;149(1-2):183-5
references.pmid: 2840300
references.citation: N Engl J Med. 1992 Oct 22;327(17):1198-203
references.pmid: 1357550
references.citation: Am J Physiol. 1993 Jul;265(1 Pt 1):C299-303
references.pmid: 8338137
references.citation: N Engl J Med. 2006 Nov 23;355(21):2226-35
references.pmid: 17124020
references.citation: J Physiol. 2001 May 1;532(Pt 3):625-35
references.pmid: 11313434
references.citation: J Allergy Clin Immunol. 1990 Nov;86(5):793-800
references.pmid: 1977787
references.citation: Clin Exp Allergy. 1998 Jun;28(6):772-7
references.pmid: 9677144
references.citation: Eur Respir J. 2007 Jul;30(1):114-33
references.pmid: 17601970
references.citation: Am J Physiol. 1998 Sep;275(3):L432-41
references.pmid: 9728037
references.citation: Clin Exp Pharmacol Physiol. 2005 Jul;32(7):503-14
references.pmid: 16026507
references.citation: J Clin Invest. 2007 May;117(5):1391-8
references.pmid: 17415415
references.citation: Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1206-16
references.pmid: 18408071
references.citation: Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1146-53
references.pmid: 16428269
references.citation: Pulm Pharmacol. 1991;4(4):218-24
references.pmid: 1666856
references.citation: Respir Res. 2007 Sep 28;8:68
references.pmid: 17903241
references.citation: J Clin Invest. 1998 Nov 1;102(9):1732-41
references.pmid: 9802887
references.citation: J Smooth Muscle Res. 2003 Dec;39(6):205-19
references.pmid: 15048013
references.citation: Neuron. 2003 Feb 6;37(3):375-8
references.pmid: 12575946
references.citation: Chest. 2006 Jan;129(1):15-26
references.pmid: 16424409
references.citation: Pharmacol Ther. 2006 Apr;110(1):103-16
references.pmid: 16356551
references.citation: Clin Rev Allergy Immunol. 2003 Feb;24(1):85-110
references.pmid: 12644720
references.citation: Trends Pharmacol Sci. 2000 Jan;21(1):16-9
references.pmid: 10637650
references.citation: J Child Neurol. 2003 Jan;18(1):39-48; discussion 49
references.pmid: 12661937
references.citation: J Appl Physiol (1985). 2004 Jan;96(1):260-70
references.pmid: 12972437
references.citation: Eur J Pharmacol. 2000 Sep 8;403(3):209-19
references.pmid: 10973621